- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01281124
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine the ability of 5-azacytidine to cause DNA hypomethylation and re-expression of silenced tumor suppressor genes when stratified for high or low expression of mir29a, b, and c.
SECONDARY OBJECTIVES:
I. To compare the molecular studies (mir29 expression and tumor suppressor gene methylation) between archival tissue, fresh biopsy pre-treatment samples, and post-treatment fresh samples.
II. To determine the overall response rate by CT (RECIST 1.1 criteria) and PET (EORTC PET response criteria), PFS, and OS of patients treated with azacytidine in the second- or third-line setting.
III. To correlate the blood microRNA profiles (and changes in microRNA profiles) with response to azacytidine.
OUTLINE:
Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo tissue and blood sample collection at baseline and periodically during study treatment for correlative studies. After completion of study treatment, patients are followed up for 12 weeks.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Advanced (stage 4 or recurrent) NSCLC, not eligible for any curative intent treatment
- Tumor must be histologically or cytologically confirmed
- Measurable disease (as defined by RECIST criteria)
Patients may have up to two (and at least one) prior cytotoxic regimens in the metastatic setting
- Prior adjuvant chemotherapy following resection or definitive chemo-radiation for patients with locally advanced disease is not included in this
- Allowable systemic therapy in the metastatic setting includes 2 cytotoxic regimens and erlotinib and/or other non-cytotoxic drugs (i.e., erlotinib, sorafenib, and other tyrosine kinase inhibitors do not count as a "cytotoxic regimen")
- Prior adjuvant therapy or definitive chemo-radiation is allowed if completed > six months before the onset of "first-line" therapy in the metastatic setting - in this setting, adjuvant or definitive chemo-radiation will not "count" as one of the two cytotoxic regimens; if however, the patient relapses within six months from completion of adjuvant or definitive chemoradiation, then this therapy will be considered the first-line cytotoxic therapy
- In the unusual circumstance where patients receive "adjuvant" therapy following resection of oligo-metastatic disease (for example brain metastasis and lung primary resections) and the treating physician decides to administer chemotherapy following all surgery, this will be considered "adjuvant" therapy and the same rules as noted above will apply for initiation of first-line systemic therapy
No patients with uncontrolled brain metastases or leptomeningeal disease
- Patients with controlled brain metastases are allowed
- ECOG performance status 0-2
- Absolute neutrophil count ≥ 1.5 x 10^9/L
- Platelets ≥ 100,000 x 10^9/L
- Hemoglobin ≥ 9.0 gm/100 mL
- Total bilirubin ≤ 1.5 mg/dL
- AST and ALT ≤ 2.5 x ULN
- Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance > 50 mL/min
- No patients who are pregnant
- Women of childbearing potential must have a negative pregnancy test
- The patient must be willing to use adequate contraception for the duration of study treatment and up to four weeks following the last dose of drug
Archival diagnostic material sufficient for microRNA evaluation/assessment is preferred, though optional
- The presence of archival material will not preclude the need for pre and post treatment biopsies
Willing to undergo biopsy pre-treatment and following first cycle
- Biopsy may be from any accessible site (primary or metastatic)
- No known HIV or hepatitis B or C (though testing for this is not required)
No uncontrolled intercurrent illness including, but not limited to:
- Symptomatic CHF
- Unstable angina pectoris
- Serious cardiac arrhythmia
- Serious infection
- Psychiatric illness or social situations that would limit compliance with study requirements
- No patients who have significant psychiatric illness that, in the opinion of the principal investigator, would prevent adequate informed consent or render therapy unsafe
Patients may not have had a prior invasive malignancy except for adequately treated non-melanoma cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 2 years
- For example, a stage 1 (T1c) prostate cancer 2 years prior to a diagnosis of NSCLC would not be exclusionary, however, a metastatic prostate cancer currently receiving hormonal or chemotherapy would be excluded
- No other concurrent palliative radiotherapy
- Recovered from prior surgery, radiation, or chemotherapy to ≤ grade 2 toxicity
- Palliative radiation or surgical procedures (for example, endobronchial therapy) is allowed, but must have been completed > 2 weeks prior to starting treatment
- No other investigational or commercial agents or therapies may be administered with the intent to treat the patient's malignancy
- No other concurrent investigational therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Treatment (azacitidine)
Patients receive azacitidine subcutaneously on days 1-7.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Korrelativa studier
Korrelativa studier
Given subcutaneously
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29
Tidsram: Up to 12 weeks after completion of study treatment
|
The change in mean methylation of the genes between the patients with a low mir29 and a high mir29 expression will be evaluated by a two-sample t-test.
Secondary analyses include a multivariate regression where all 5 changes in methylation will be regressed on mir29 expression (low vs. high) and adjusted for patient demographic and clinical attributes at baseline.
|
Up to 12 weeks after completion of study treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall Survival
Tidsram: From the day of initial treatment until death (from any cause), assessed up to 12 weeks after completion of study treatment
|
Analyzed using a Kaplan-Meier methods.
|
From the day of initial treatment until death (from any cause), assessed up to 12 weeks after completion of study treatment
|
Progression-free Survival
Tidsram: From the day of initial treatment until documented disease progression (per PET) or death, assessed up to 12 weeks after completion of study treatment
|
Analyzed using a Kaplan-Meier methods.
|
From the day of initial treatment until documented disease progression (per PET) or death, assessed up to 12 weeks after completion of study treatment
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Gregory A Otterson, Ohio State University Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Azacitidin
Andra studie-ID-nummer
- NCI-2011-02570 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- P30CA016058 (U.S.S. NIH-anslag/kontrakt)
- N01CM00070 (U.S.S. NIH-anslag/kontrakt)
- CDR0000692184
- OSU-10100
- OSU 10100 (Annan identifierare: Ohio State University Comprehensive Cancer Center)
- 8617 (Annan identifierare: CTEP)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Återkommande icke-småcelligt lungkarcinom
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
Bristol-Myers SquibbAvslutadNjurcellscancer | Non-hodgkins lymfomFörenta staterna
-
National Cancer Institute (NCI)IndragenAvancerat lymfom | Avancerad malignt fast neoplasma | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt lymfom | Eldfast malignt fast neoplasma | Refraktär pankreascancer | Refraktärt T-cell non-Hodgkin lymfom | Steg II pankreascancer AJCC v8 | Steg III pankreascancer AJCC v8 | Steg IV Bukspottkörtelcancer... och andra villkor
-
Mayo ClinicNational Cancer Institute (NCI)UpphängdÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande bröstkarcinom | Återkommande Mycosis Fungoides | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg IV Bröstcancer AJCC v6 och v7 | Adenocarcinom i bröstet | Metastaserande... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringAvancerat lymfom | Avancerad malignt fast neoplasma | Avancerat pankreascancer | B-cells non-Hodgkin lymfom | Metastaserande pankreascancer | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt lymfom | Eldfast malignt fast neoplasma | Refraktär pankreascancer | Refraktärt T-cell non-Hodgkin lymfom | Steg II... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeSezary syndrom | Refraktärt T-cell non-Hodgkin lymfom | Merkel cellkarcinom | Anaplastiskt storcelligt lymfom, ALK-positivt | Extramammär Pagetsjuka | Återkommande T-cell non-Hodgkin lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)IndragenMetastatisk malign fast neoplasma | Ooperbar fast neoplasma | Steg IIIB hepatocellulärt karcinom AJCC v7 | Steg IIIC hepatocellulärt karcinom AJCC v7 | Ann Arbor Steg IV B-cell non-Hodgkin lymfom | Ann Arbor Steg III B-cell non-Hodgkin lymfom | Steg IV hepatocellulärt karcinom AJCC v7 | Steg III hepatocellulärt... och andra villkorFörenta staterna
-
Opna-IO LLCAvslutadFollikulärt lymfom | Småcellig lungcancer | Fast tumör | Non-Hodgkin lymfom | Diffust stort B-cellslymfom | Ovarian clear cell carcinoma | Uveal melanom | Avancerade maligniteterFörenta staterna
-
Epizyme, Inc.Anmälan via inbjudanAvancerade solida tumörer | Mesoteliom | Synovialt sarkom | Njurmärgkarcinom | Diffust stort B-cellslymfom (DLBCL) | Follikulärt lymfom (FL) | Non-Hodgkin lymfom (NHL) | Epiteloid sarkom (ES)Förenta staterna, Frankrike, Storbritannien, Polen, Australien, Belgien, Ukraina
-
National Cancer Institute (NCI)AvslutadÅterkommande vuxen Burkitt lymfom | Återkommande vuxen diffust storcelligt lymfom | Återkommande vuxen diffust blandat celllymfom | Återkommande vuxen diffust småcelligt lymfom | Återkommande vuxen lymfatisk lymfom | Återkommande follikulärt lymfom grad 1 | Återkommande follikulärt lymfom grad 2 | Återkommande... och andra villkorFörenta staterna
Kliniska prövningar på Farmakologisk studie
-
Tampere University HospitalAvslutad
-
Radicle ScienceAktiv, inte rekryterandeKognitiv funktionFörenta staterna
-
University of MichiganAvslutad
-
Scion NeuroStimAnmälan via inbjudanParkinsons sjukdom | Parkinsons sjukdom och ParkinsonismFörenta staterna
-
Apple Inc.Stanford UniversityAvslutadFörmaksflimmer | Arytmier, hjärt | FörmaksfladderFörenta staterna
-
Boston Scientific CorporationAvslutadVentrikulär takykardiAustralien
-
Radicle ScienceRekryteringSmärta | Neuropatisk smärta | Nociceptiv smärtaFörenta staterna
-
Brock UniversityDairy Farmers of CanadaAvslutadFetma | Övervikt | BarnKanada
-
Radicle ScienceAktiv, inte rekryterandePåfrestning | ÅngestFörenta staterna